Aera Therapeutics
aeratx.com
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Aera Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, MA, September 1, 2026 - Aera Therapeutics, a biotechnology company harnessing next-generation delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced that management will participate in tw
Read more
Report
Aera Therapeutics to Present Preclinical Data on AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases, at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., December 02, 2025--Aera Therapeutics, a biotechnology company harnessing next-generation delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced an upcoming poster presentation on A
Read more
Report
Aera Therapeutics to Present Preclinical Data on AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases, at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, MA, December 2, 2025 - Aera Therapeutics, a biotechnology company harnessing next-generation delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced an upcoming poster presentation on AERA
Read more
Report
Aera Therapeutics Announces Participation in Upcoming Investor Conferences
Aera Therapeutics Announces Participation in Upcoming Investor Conferences CAMBRIDGE, MA, November 5, 2025 - Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full pot
Read more
Report
Aera Therapeutics selects AERA-109 for autoimmune diseases
Aera Therapeutics Inc. has nominated AERA-109, a targeted in vivo CAR T therapy designed to treat multiple B cell-mediated autoimmune diseases, as the company's first development candidate. AERA-109 leverages Aera's proprietary targeted lipid nanoparticle
Read more
Report
Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases
CAMBRIDGE, Mass., September 24, 2025--Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today presented preclinical data at the 10
Read more
Report
Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases
Preclinical data presented at the 10th Annual CAR-TCR Summit demonstrated deep depletion of B cells in blood and tissue in humanized mouse models and non-human primates, supporting nomination of AERA-109 as Aera's first development candidate Aera plans to
Read more
Report
Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific Officer
BOSTON, MA, September 2, 2025 - Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of William Querb
Read more
Report
Aera Therapeutics Appoints Paul Conrad, Ph.D., MBA, as Chief Business and Financial Officer
BOSTON, MA, May 12, 2025 - Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of Paul Conrad, Ph.D.
Read more
Report
Show more news